




CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Ellen Ciambrone Coletti

(Print Name)

Date: May 30, 1995

  
(Signature)

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent

(Inventors): Quirico Branca, Roland Jaunin, Hans Peter Märki,  
Fränzi Marti, Henri Ramuz

Patent No. 4,808,605, issued February 28, 1989

Assigned to Hoffmann-La Roche Inc.

(Serial No. 07/119,114, filed November 10, 1987)

For: **TETRAHYDRONAPHTHALENE DERIVATIVES AS CALCIUM ANTAGONISTS**

REQUEST FOR CERTIFICATE OF CORRECTION

Nutley, New Jersey 07110  
May 30, 1995

Honorable Commissioner of Patents & Trademarks  
Washington, D.C. 20231

Sir:

Attention is called to errors which appear in both the specification and claims of the above patent. These errors are set forth in the enclosed Certificate of Correction Form PTO 1050. Request is hereby made for issuance of a Certificate of Correction.

KM12010 07/28/95 4808605

08-2525 120 145 100.00CH


RECEIVED

JUN 13 95

CERTIFICATE  
OF  
CORRECTION  
OF  
PATENT  
NO. 4,808,605  
FILED  
IN  
THE  
OFFICE  
OF  
THE  
COMMISSIONER  
OF  
PATENTS  
&  
TRADEMARKS  
WASHINGTON, D.C.

APPROVED

SEP 15 1995



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

Page 1 of 9

PATENT NO. : 4,808,605  
 DATED : February 28, 1989  
 INVENTOR(S): Quirico Branca, Roland Juanin, Hans Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE SPECIFICATION

- Column 2, line 11, "and the 106 like" should read  
 --- and the like --- .
- Column 8, line 42, "acidiin" should read  
 --- acid in --- .
- Column 14, line 63, in the Table, letter G "[1S,2S]-2,6-Fluoro" should read --- [1S,2S]-6-Fluoro --- .
- Columns 17-18, line 40, "heated to 0°" should read  
 --- heated to 70° --- .
- Column 18, line 52, "[1S,2S]-2-[2755- " should read  
 --- [1S,2S]-2-[2- --- .
- Column 19, lines 12-13, "-isopropyl-2 $\beta$ -naphthalenol" should read --- -isopropyl-2-naphthalenol --- .
- Column 19, line 15, "1 $\alpha$ -isopropyl-2 $\delta$ -naphthyl" should read --- 1 $\alpha$ -isopropyl-2 $\beta$ -naphthyl --- .
- Column 20, line 38, "Thereafter." should read  
 --- Thereafter, --- .
- Column 21, line 65, "(37.2% of" should read  
 --- (37.2%) of --- .
- Column 22, line 4, "of 6997-fluoro" should read  
 --- of 6-fluoro --- .

MAILING ADDRESS OF SENDER:

Hoffmann-La Roche Inc.  
 340 Kingsland Street  
 Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l. copies  
 @ 30¢ per page

➔ 1 of 9

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,605  
DATED : February 28, 1989  
INVENTOR(S) : Quirico Branca, Roland Juanin, Hans  
Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

*note*  
IN THE SPECIFICATION

- Column 22, line 5, "tetrahydro-2-isopropyl-2,hydroxy" should read --- tetrahydro-2-hydroxy --- .
- Column 23, line 34, "an anaogous manner" should read --- an analogous manner --- .
- Column 25, line 22, "water.dried over" should read --- water, dried over --- .
- Column 26, line 6, "Thereafter." should read --- Thereafter, --- .
- Column 26, line 21, "benzimiazoliny]" should read --- benzimidazoliny] --- . *atty*
- Column 26, line 58, "1-[6-[[2-[[7S,2S]- " should read --- 1-[6-[[2-[[1S,2S]- --- .
- Column 27, line 37, "analogous" should read --- analogous --- .
- Column 28, line 53, "2hydroxy-" should read --- 2-hydroxy- --- . *atty*
- Column 29, line 47, "anaIogous" should read --- analogous --- .

MAILING ADDRESS OF SENDER:  
Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l. copies  
@ 30¢ per page

➡ 2 of 9

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,605  
DATED : February 28, 1989  
INVENTOR(S) : Quirico Branca, Roland Juanin, Hans  
Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

*note*  
IN THE SPECIFICATION

- ✓ Column 29, line 47, "lhat" should read --- that --- . C
- ✓ Column 30, line 4, "With" should read --- with --- . C
- ✓ Column 30, line 22, "1.2,3,4-tetrahydro" should read  
--- 1,2,3,4-tetrahydro --- . C
- ✓ Column 30, line 53, "[4.5-c]" should read  
--- [4,5-c] --- . C
- ✓ Column 30, line 55, "[4.5-c]" should read  
--- [4,5-c] --- . C
- ✓ Column 32, line 24, "water." should read  
--- water, --- . C
- ✓ Column 32, line 44, " (0 005 mol)" should read  
--- (0.005 mol) --- . C
- ✓ Column 33, line 10, " -4.5-" should read  
--- -4,5-, --- . C
- ✓ Column 33, line 15, "sodium chloride.dried"  
should read --- sodium chloride, dried --- . C

MAILING ADDRESS OF SENDER:  
Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l. copies  
@ 30¢ per page

➔ 3 of 9

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 4,808,605  
DATED : February 28, 1989  
INVENTOR(S) : Quirico Branca, Roland Juanin, Hans  
Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE SPECIFICATION

Column 33, line 57, " N-methyl-4.5- " should read  
--- -N-methyl-4,5- --- . *Atty*

Column 34, line 55, " -4.5- " should read  
--- -4,5- --- . *C*

Column 34, line 59, "analoqous" should read  
--- analogous --- . *C*

Column 35, line 17, " (ppE) " should read  
--- (PPE) --- . *C*

Column 35, line 21, "minuIes" should read  
--- minutes --- . *C*

Column 35, lines 46-47, " [5.4,0] " should read  
--- [5.4.0] --- . *C*

Column 35, lines 65-66, " (0 12) " should read  
--- (0.12) --- . *Atty* *mol*

Column 36, line 3, "The organic phase." should read  
--- The organic phase, --- . *C*

Column 36, line 19, "The product.isolated" should read  
--- The product, isolated --- . *C*

MAILING ADDRESS OF SENDER:  
Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l copies  
@ 50¢ per page

4 of 9

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,605  
DATED : February 28, 1989  
INVENTOR(S) : Quirico Branca, Roland Juanin, Hans  
Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

*Note*  
IN THE SPECIFICATION

Column 37, line 36, "analoqous" should read  
--- analogous --- . C

Column 37, line 49, "A solutionof" should read  
--- A solution of --- . C

Column 37, line 64, "ice-water The" should read  
--- ice-water. The --- . C

Column 39, line 15, "The product.isolated in"  
should read --- The product, isolated in --- . C

Column 39, line 31, " -1,4-benzodiazepine-2.5-(1H) - "  
should read --- -1,4-benzodiazepine-2,5-(1H) - --- . C

Column 39, line 37, " [1,4]benzodiazepine-5.11-(10H) "  
should read --- [1,4]benzodiazepine-5,11-(10H) --- . C

Column 40, lines 47-48, " -5.11- " should read  
--- -5,11- ---- . C

MAILING ADDRESS OF SENDER:  
Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l. copies  
@ 30¢ per page



5 of 9

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 4,808,605  
DATED : February 28, 1989  
INVENTOR(S) : Quirico Branca, Roland Juanin, Hans  
Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

*Note*  
~~IN THE SPECIFICATION~~

Column 40, line 48, "[2.1-c][1.4]" should read  
--- [2,1-c][1,4] --- . C

Column 41, line 3, "granuolated" should read  
--- granulated --- . C

Column 41, line 25, "Manufacutring" should read  
--- Manufacturing --- . C

Column 41, line 28, "resulitng" should read  
--- resulting --- . C

Column 41, line 49, "therafter" should read  
--- thereafter --- . C

Column 42, line 5, "mixtture" should read  
--- mixture --- . C

Column 42, line 22, "intesnively" should read  
--- intensively --- . C

Column 42, line 24, "odium" should read  
--- sodium --- . C

Column 42, lines 24-25, "magniesium" should read  
--- magnesium --- . C

Column 42, line 41, "followed.tablets" should read  
--- followed, tablets --- . C

MAILING ADDRESS OF SENDER:  
Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l copies  
@ 50¢ per page  
6 of 9

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,605  
DATED : February 28, 1989  
INVENTOR(S) : Quirico Branca, Roland Juanin, Hans Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

## IN THE CLAIMS

- note*
- \*Column 42, line 67, "alklamino<sup>o</sup>carbonyloxy" should read --- alkylamino<sup>o</sup>carbonyloxy --- . *atty*
  - \*Column 42, line 68, "multipliesubstituted" should read --- multiply-substituted --- . *C*
  - \*Column 43, line 10, "[4,5c]" should read --- [4,5-c] --- . *C*
  - \*Column 43, line 55, "(2-benzimidaolyl)" should read --- -(2-benzimidazolyl) --- . *C*
  - \*Column 44, lines 11-12, "lower-alklcarbonyloxy" should read --- -lower-alkyl-carbonyloxy --- . *C*
  - \*Column 44, line 13, "arylamio-carbonyloxy" should read --- arylaminocarbonyloxy --- . *C*
  - \*Column 44, line 17, "niro" should read --- nitro --- . *C*
  - \*Column 44, lines 18-19, "intrrupted" should read --- interrupted --- . *C*
  - \*Column 44, line 25, "pyridinyl" should read --- pyridinonyl --- . *C*

MAILING ADDRESS OF SENDER:  
Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l copie  
@ 50¢ per pag  
7 of 9



# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,605  
 DATED : February 28, 1989  
 INVENTOR(S) : Quirico Branca, Roland Juanin, Hans Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

## IN THE CLAIMS

- Column 44, lines 27-28, "[1,4benzodiazepine-" should read ---[1,4]benzodiazepine---. *C*
- Column 44, line 44, "(2-benzimidazolyl)propyl]methyl-amio]ethyl " should read --- (2-benzimidazolyl)propyl] methyl- amino]ethyl ---. *atty*
- Column 44, lines 47-48, "petcoris" should read --- pectoris ---. *C*
- Column 44, line 48, "arrhydhmias" should read --- arrhythmias ---. *C*
- Column 44, line 51, "calcuim" should read --- calcium ---. *C*
- Column 44, line 66, "aryl-lower-alkylamio-carbonyloxy" should read ---aryl-lower-alkyl-aminocarbonyloxy---. *atty*
- Column 44, line 67, "multipliesubstituted" should read --- multiply-substituted ---. *C*
- Column 45, line 9, "bezthiazoyl" should read --- benzthiazolyl ---. *C*

MAILING ADDRESS OF SENDER:  
 Hoffmann-La Roche Inc.  
 340 Kingsland Street  
 Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l copie  
 @ 50¢ per pag  
 8 of 9

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 4,808,605  
DATED : February 28, 1989  
INVENTOR(S) : Quirico Branca, Roland Juanin, Hans  
Peter Märki, Fränz Marti, Henri Ramuz

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**IN THE CLAIMS**

- Column 46, line 2, "phamraceutically" should read  
--- pharmaceutically --- . C
- Column 46, line 4, "Claim 19 wherein" should read  
--- Claim 19, wherein --- . C
- Column 46, line 8, "hexameethylene" should read  
--- hexamethylene --- . C

MAILING ADDRESS OF SENDER:

Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, N.J. 07110

PATENT NO. 4,808,605

No. of add'l copies  
@ 50¢ per page

→ 9 of 9

The exact page and line numbers where the errors occur in the application file are as follows:

**IN THE SPECIFICATION**

- Page 3, line 2, (corresponding to Column 2, line 11 of the printed patent) "and the 106 like" should read --- and the like --- .
- Page 14, line 27, (corresponding to Column 8, line 42 of the printed patent) "acidiin" should read --- acid in --- .
- Page 23, line 7, (corresponding to Column 14, line 63 of the printed patent, in the Table, letter G) "[1S,2S]-2,6-Fluoro" should read --- [1S,2S]-6-Fluoro --- .
- Page 28, lines 17-18, (corresponding to Column 17, line 40 of the printed patent) "heated to 0°" should read --- heated to 70° --- .
- Page 30, line 36, (corresponding to Column 18, line 52 of the printed patent) " [1S,2S]-2-[2755- " should read --- [1S,2S]-2-[2- --- .
- Page 31, lines 31-32, (corresponding to Column 19, lines 12-13 of the printed patent) "-isopropyl-2 $\beta$ -naphthalenol" should read --- -isopropyl-2-naphthalenol --- .

- Page 31, line 35, (corresponding to Column 19, line 15 of the printed patent) "1 $\alpha$ -isopropyl-28-naphthyl" should read --- 1 $\alpha$ -isopropyl-2 $\beta$ -naphthyl --- .
- Page 34, line 22, (corresponding to Column 20, line 38 of the printed patent) "Thereafter." should read --- Thereafter, --- .
- Page 37, line 8, (corresponding to Column 21, line 65 of the printed patent) "(37.2% of" should read --- (37.2%) of --- .
- Page 37, line 17, (corresponding to Column 22, line 4 of the printed patent) " of 6997-fluoro" should read --- of 6-fluoro --- .
- Page 37, line 18, (corresponding to Column 22, line 5 of the printed patent) "tetrahydro-2-isopropyl-2-hydroxy" should read --- tetrahydro-2-hydroxy --- .
- Page 40, line 5, (corresponding to Column 23, line 34 of the printed patent) "an anaoogous manner" should read --- an analogous manner --- .
- Page 43, line 21, (corresponding to Column 25, line 22 of the printed patent) "water.dried over" should read --- water, dried over --- .

- Page 45, line 3, (corresponding to Column 26, line 6 of the printed patent) "Thereafter." should read  
--- Thereafter, --- .
- Page 45, line 19, (corresponding to Column 26, line 21 of the printed patent) "benzimidazoliny]" should read  
--- benzimidazoliny]- --- .
- Page 46, line 20, (corresponding to Column 26, line 58 of the printed patent) "1-[6-[[2-[[7S,2S]- " should read  
--- 1-[6-[[2-[[1S,2S]- --- .
- Page 47, line 33, (corresponding to Column 27, line 37 of the printed patent) "analogous" should read  
--- analogous --- .
- Page 50, lines 4-5, (corresponding to Column 28, line 53 of the printed patent) "2hydroxy-" should read  
--- 2-hydroxy- --- .
- Page 51, line 37, (corresponding to Column 29, line 47 of the printed patent) "analogous" should read  
--- analogous --- .
- Page 51, line 37, (corresponding to Column 29, line 47 of the printed patent) "lhat" should read --- that --- .

- Page 52, line 26, (corresponding to Column 30, line 4 of the printed patent) "With" should read --- with --- .
- Page 53, line 8, (corresponding to Column 30, line 22 of the printed patent) "1.2,3,4-tetrahydro" should read --- 1,2,3,4-tetrahydro --- .
- Page 54, line 5, (corresponding to Column 30, line 53 of the printed patent) "[4.5-c]" should read --- [4,5-c] --- .
- Page 54, line 8, (corresponding to Column 30, line 55 of the printed patent) "[4.5-c]" should read --- [4,5-c] --- .
- Page 57, line 15, (corresponding to Column 32, line 24 of the printed patent) "water." should read --- water, --- .
- Page 57, line 35, (corresponding to Column 32, line 44 of the printed patent) " (0 005 mol)" should read --- (0.005 mol) --- .
- Page 58, line 36, (corresponding to Column 33, line 10 of the printed patent) " -4.5-" should read --- -4,5- --- .
- Page 59, line 3, (corresponding to Column 33, line 15 of the printed patent) "sodium chloride.dried" should read --- sodium chloride, dried --- .

- Page 60, line 10, (corresponding to Column 33, line 57 of the printed patent) " N-methyl-4.5- " should read  
--- -N-methyl-4,5- --- .
- Page 62, line 1, (corresponding to Column 34, line 55 of the printed patent) " -4.5- " should read --- -4,5- --- .
- Page 62, line 6, (corresponding to Column 34, line 59 of the printed patent) "analogous" should read --- analogous --- .
- Page 62, line 34, (corresponding to Column 35, line 17 of the printed patent) " (ppE)" should read --- (PPE) --- .
- Page 63, line 1, (corresponding to Column 35, line 21 of the printed patent) "minuIes" should read --- minutes --- .
- Page 63, line 27, (corresponding to Column 35, lines 46-47 of the printed patent) " [5.4,0] " should read  
--- [5.4.0] --- .
- Page 64, line 9, (corresponding to Column 35, lines 65-66 of the printed patent) " (0 12)" should read --- (0.12) --- .
- Page 64, lines 14-15, (corresponding to Column 36, line 3 of the printed patent) "The organic phase." should read  
--- The organic phase, --- .

- Page 64, line 31, (corresponding to Column 36, line 19 of the printed patent) "The product.isolated" should read --- The product, isolated --- .
- Page 67, line 8, (corresponding to Column 37, line 36 of the printed patent) "analoqous" should read --- analogous --- .
- Page 67, line 23, (corresponding to Column 37, line 49 of the printed patent) "A solutionof" should read --- A solution of --- .
- Page 68, line 1, (corresponding to Column 37, line 64 of the printed patent) "ice-water The" should read --- ice-water. The --- .
- Page 70, line 17, (corresponding to Column 39, line 15 of the printed patent) "The product.isolated in" should read -- - The product, isolated in --- .
- Page 70, line 34, (corresponding to Column 39, line 31 of the printed patent) " -1,4-benzodiazepine-2.5-(1H)- " should read --- -1,4-benzodiazepine-2,5-(1H)- --- .
- Page 71, line 5, (corresponding to Column 39, line 37 of the printed patent) " [1,4]benzodiazepine-5.11-(10H) " should read --- [1,4]benzodiazepine-5,11-(10H) --- .



- Page 73, line 17, (corresponding to Column 40, lines 47-48 of the printed patent) " -5.11- " should read  
--- -5,11- --- .
- Page 73, line 17, (corresponding to Column 40, line 48 of the printed patent) " [2.1-c][1.4] " should read  
--- [2,1-c][1,4] --- .
- Page 74, line 23, (corresponding to Column 41, line 3 of the printed patent) " granuolated " should read  
--- granulated --- .
- Page 75, line 22, (corresponding to Column 41, line 25 of the printed patent) "Manufacutring" should read  
--- Manufacturing --- .
- Page 75, line 26, (corresponding to Column 41, line 28 of the printed patent) "resulitng" should read  
--- resulting --- .
- Page 76, line 23, (corresponding to Column 41, line 49 of the printed patent) "therafter" should read  
--- thereafter --- .
- Page 77, line 23, (corresponding to Column 42, line 5 of the printed patent) "mixtture" should read --- mixture --- .

- Page 78, line 19, (corresponding to Column 42, line 22 of the printed patent) "intesnively" should read  
--- intensively --- .
- Page 78, line 21, (corresponding to Column 42, line 24 of the printed patent) "odium" should read --- sodium --- .
- Page 78, line 21, (corresponding to Column 42, lines 24-25 of the printed patent) "magniesium" should read  
--- magnesium --- .
- Page 79, line 4, (corresponding to Column 42, line 41 of the printed patent) "followed.tablets" should read  
--- followed, tablets --- .

## IN THE CLAIMS


- Claim 1, Column 42, line 67 of the printed patent:  
"alklamino-carbonyloxy" should read --- alkylamino-carbonyloxy --- . (Corresponding to Claim 22, in the September 27, 1988 Amendment).
- Claim 1, Column 42, line 68 of the printed patent:  
"multipliesubstituted" should read  
--- multiply-substituted --- . (Corresponding to Claim 22, in the September 1988 Amendment).
- Claim 1, Column 43, line 10 of the printed patent: "[4,5c]" should read --- [4,5-c] --- . (Corresponding to Claim 22, in the September 27, 1988 Amendment).
- Claim 13, Page 82, line 2, (corresponding to Column 43, line 55 of the printed patent) " (2-benzimidaoilyl)" should read  
--- -(2-benzimidazolyl) --- .
- Claim 16, Column 44, lines 11-12 of the printed patent:  
"lower-alklcarbonyloxy" should read --- -lower-alkyl-carbonyloxy --- . (Corresponding to Claim 23, in the September 27, 1988 Amendment).

- Claim 16, Column 44, line 13 of the printed patent:  
"arylamio-carbonyloxy" should read ---  
arylamino-carbonyloxy --- . (Corresponding to Claim 23, in  
the September 27, 1988 Amendment).
- Claim 16, Column 44, line 17 of the printed patent: "niro"  
should read --- nitro --- . (Corresponding to Claim 23, in  
the September 27, 1988 Amendment).
- Claim 16, Column 44, lines 18-19 of the printed patent:  
"intrrupted" should read --- interrupted --- .  
(Corresponding to Claim 23, in the September 27, 1988  
Amendment).
- Claim 16, Column 44, line 25 of the printed patent:  
"pyridinyl" should read --- pyridinonyl --- .  
(Corresponding to Claim 23, in the September 27, 1988  
Amendment).
- Claim 16, Column 44, lines 27-28 of the printed patent:  
"[1,4benzodiazepine-" should read ---[1,4]benzodiazepine---.  
(Corresponding to Claim 23, in the September 27, 1988  
Amendment).

- Claim 18, Page 83, line 16, (corresponding to Column 44, line 44 of the printed patent) "(2-benzimidazolyl)propyl]methyলামio] ethyl " should read --- (2-benzimidazolyl)propyl]methyলামino]ethyl --- .
- Claim 19, Column 44, lines 47-48 of the printed patent: "petcoris" should read --- pectoris --- . (Corresponding to Claim 24, in the September 27, 1988 Amendment).
- Claim 19, Column 44, line 48 of the printed patent: "arrhydhthmias" should read --- arrhythmias --- . (Corresponding to Claim 24, in the September 27, 1988 Amendment).
- Claim 19, Column 44, line 51 of the printed patent: "calcuim" should read --- calcium --- . (Corresponding to Claim 24, in the September 27, 1988 Amendment).
- Claim 19, Column 44, line 66 of the printed patent: "aryl-lower-alkylamio-carbonyloxy" should read --- aryl-lower-alkyl- aminocarbonyloxy --- . (Corresponding to Claim 24, in the September 27, 1988 Amendment).
- Claim 19, Column 44, line 67 of the printed patent: "multiplysubstituted" should read --- multiply-substituted --- . (Corresponding to Claim 24, in the September 27, 1988 Amendment).

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication to Deposit Account No. 08-2525.

Respectfully submitted,



Attorney for applicants  
Ellen Ciambrone Coletti  
(Reg. No. 34140)  
340 Kingsland Street  
Nutley, New Jersey 07110  
(201) 235-5171

Enclosures

ECColetti:JMF  
94726